Pfizer-Valneva Lyme Vaccine Faces Approval Hurdles After Missing Study Mark

Pfizer and Valneva's Lyme disease vaccine trial showed strong efficacy but reportedly missed a specific mark, complicating its path to regulatory approval from the FDA, as further reports confirm.